Diagnosis and treatment of familial hypercholesterolaemia

G Kees Hovingh1, Michael H Davidson, John J P Kastelein

  • 1Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Room F4-159.2, 1105 AZ Amsterdam, The Netherlands.

European Heart Journal
|February 19, 2013
PubMed

Insights

Familial hypercholesterolaemia (FH) is a genetic disorder causing high LDL-C. Early diagnosis and new treatments are crucial for preventing cardiovascular disease in FH patients.

Area of Science:

  • Cardiovascular Genetics
  • Pharmacotherapy

Background:

  • Familial hypercholesterolaemia (FH) is an autosomal dominant disorder characterized by elevated low-density lipoprotein-cholesterol (LDL-C).
  • High LDL-C levels significantly increase the risk of premature cardiovascular disease, emphasizing the need for early diagnosis and intervention.
  • Current diagnostic methods include clinical assessment and genetic testing, with a focus on reducing LDL-C levels to prevent morbidity and mortality.

Purpose of the Study:

  • To review current and emerging treatment strategies for managing Familial hypercholesterolaemia.
  • To discuss the diagnostic approaches for FH, including clinical and genetic testing.
  • To highlight the importance of achieving target LDL-C levels in FH patients.

Main Methods:

  • Review of current literature on FH diagnosis and treatment.
  • Analysis of existing guidelines for LDL-C management in FH.
  • Exploration of novel pharmacotherapies targeting LDL-C metabolism.

Main Results:

  • Statins are the standard treatment but many FH patients do not reach target LDL-C levels.
  • New drug classes are under investigation, including agents inhibiting apolipoprotein B and pro-protein convertase subtilisin/kexin 9 (PCSK9).
  • Therapies aimed at increasing high-density lipoprotein cholesterol are also being evaluated.

Conclusions:

  • Effective management of FH requires a multi-faceted approach including early diagnosis and aggressive LDL-C lowering.
  • Novel therapeutic agents show promise in improving LDL-C control beyond current standards.
  • Continued research into FH treatment is essential to reduce the cardiovascular burden associated with this genetic disorder.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
434
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
572
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.2K
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.8K